Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655824 | 0.92 | GCGR (0.50) | GCGRSMN1; SMN2GCG | |
| SCHEMBL15958535 | 0.91 | GCGR (0.47) | GCGRL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL2669967 | 0.87 | GCGR (0.48) | GCGRL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL1393538 | 0.86 | GCGR (0.47) | GCGRL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL1394048 | 0.83 | GCGR (0.46) | GCGRL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL2657995 | 0.81 | CYP2C9 (0.45) | L3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL2658923 | 0.80 | GCGR (0.45) | GCGRSMN1; SMN2 | |
| SCHEMBL2669997 | 0.78 | GCGR (0.49) | GCGRSMN1; SMN2 | |
| SCHEMBL2525872 | 0.78 | GCGR (0.49) | GCGRSMN1; SMN2 | |
| SCHEMBL15958540 | 0.78 | RAB9A (0.45) | GCGRMEN1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809579-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. | 2011-12-22 | — | — | US | disclosed |
| WO-2010098948-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAININ SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | GCGR 1/4885L3MBTL1 4596/4885MEN1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.